75 studies found for:    "Germinoma"
Show Display Options
Rank Status Study
1 Recruiting Cause of Familial Testicular Cancer
Conditions: Testicular Neoplasms;   Germinoma
Intervention:
2 Completed Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Conditions: Childhood Burkitt Lymphoma;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Medulloepithelioma;   Childhood Meningioma;   Childhood Mixed Glioma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Childhood Oligodendroglioma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis
3 Completed Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Visual Pathway Glioma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride;   Other: pharmacological study
4 Completed Sunitinib in Treating Young Patients With Refractory Solid Tumors
Conditions: Central Nervous System Metastases;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: laboratory biomarker analysis
5 Completed Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Extra-adrenal Paraganglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: Drug: vorinostat;   Drug: temozolomide;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
6 Completed Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: oxaliplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Other: pharmacological study;   Procedure: positron emission tomography;   Procedure: computed tomography
7 Terminated Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood Infratentorial Ependymoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Gonadotroph Adenoma;   Pituitary Basophilic Adenoma;   Pituitary Chromophobe Adenoma;   Pituitary Eosinophilic Adenoma;   Prolactin Secreting Adenoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Pituitary Tumor;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   TSH Secreting Adenoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: dexamethasone
8 Recruiting Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Conditions: Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma
Interventions: Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide
9 Not yet recruiting Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Extracranial Germ Cell Tumor;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Medulloepithelioma;   Childhood Supratentorial Ependymoma;   Childhood Teratoma;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Retinoblastoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: etoposide;   Drug: ifosfamide;   Drug: carboplatin;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Other: laboratory biomarker analysis
10 Active, not recruiting
Has Results
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
Conditions: Brain Tumor;   Central Nervous System Tumor
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Radiation: radiation therapy
11 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
Conditions: Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor
Interventions: Biological: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine;   Other: laboratory biomarker analysis
12 Active, not recruiting Psychosexual Intervention in Patients With Stage I-III Gynecologic Cancer
Conditions: Leydig Cell Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Stage I Gestational Trophoblastic Tumor;   Stage I Uterine Sarcoma;   Stage I Vaginal Cancer;   Stage I Vulvar Cancer;   Stage IA Cervical Cancer;   Stage IA Endometrial Carcinoma;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Cervical Cancer;   Stage IB Endometrial Carcinoma;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage IC Primary Peritoneal Cavity Cancer;   Stage II Endometrial Carcinoma;   Stage II Gestational Trophoblastic Tumor;   Stage II Uterine Sarcoma;   Stage II Vaginal Cancer;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Cervical Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage III Gestational Trophoblastic Tumor;   Stage III Uterine Sarcoma;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration;   Procedure: quality-of-life assessment;   Other: behavioral, psychological or informational intervention
13 Active, not recruiting Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Conditions: Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Ovarian Germ Cell Tumor;   Stage III Malignant Testicular Germ Cell Tumor;   Stage IV Extragonadal Non-seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Ovarian Germ Cell Tumor
Interventions: Drug: alvocidib;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil
14 Terminated Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Conditions: Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Stomach;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Ovarian Mucinous Cystadenocarcinoma;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Drug: capecitabine;   Drug: oxaliplatin;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Not yet recruiting Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: metformin hydrochloride;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis
16 Terminated Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Conditions: Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Malignant Tumor of Peritoneum;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor
Interventions: Radiation: stereotactic body radiation therapy;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: questionnaire administration;   Radiation: fludeoxyglucose F 18
17 Completed Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Conditions: Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Burkitt Lymphoma;   Adult Diffuse Large Cell Lymphoma;   Adult Diffuse Mixed Cell Lymphoma;   Adult Diffuse Small Cleaved Cell Lymphoma;   Adult Hodgkin Lymphoma;   Adult Immunoblastic Large Cell Lymphoma;   Adult Lymphoblastic Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Breast Cancer;   Chronic Eosinophilic Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Cutaneous T-cell Non-Hodgkin Lymphoma;   Disseminated Neuroblastoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Malignant Testicular Germ Cell Tumor;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Multiple Myeloma;   Mycosis Fungoides/Sezary Syndrome;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neutropenia;   Nodal Marginal Zone B-cell Lymphoma;   Ovarian Epithelial Cancer;   Ovarian Germ Cell Tumor;   Plasma Cell Neoplasm;   Poor Prognosis Metastatic Gestational Trophoblastic Tumor;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
18 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis
19 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
20 Unknown  Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
Conditions: Brenner Tumor;   Cognitive/Functional Effects;   Ovarian Carcinosarcoma;   Ovarian Choriocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Dysgerminoma;   Ovarian Embryonal Carcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mixed Germ Cell Tumor;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Polyembryoma;   Ovarian Sarcoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Stromal Cancer;   Ovarian Teratoma;   Ovarian Undifferentiated Adenocarcinoma;   Ovarian Yolk Sac Tumor;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Procedure: cognitive assessment;   Procedure: quality-of-life assessment

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years